HomeAI · summaries
Storia in 3 fonti
Medline stock is a little too expensive to buy post IPO, Jim Cramer says
CNBC's Jim Cramer reviewed Medline, a medical supplies giant that made its market debut Wednesday.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Medline CEO on IPO: This is the right time for us to expand our voice
Medline CEO Jim Boyle joins 'Squawk Box' to discuss the company's IPO, the private equity involved and much more.
- ·
Medical supply firm Medline jumps more than 20% in debut after biggest IPO of 2025
Medline priced at $29 per share on Tuesday, raising $6.26 billion to cap off a strong year for new listings and bolster optimism about 2026.
- ·
forbes.com
Medline Soars 30% After $6.26 Billion IPO
The medical supply distributor raised about $6.26 billion in a blockbuster IPO on Tuesday.
- ·
upi.com
Medline shares rise 41% amid year’s largest IPO - UPI.com
The share price of medical supplies titan Medline rose by 40% during Wednesday's trading on the first day of its initial public offering.
- ·
Medline stock is a little too expensive to buy post IPO, Jim Cramer says
CNBC's Jim Cramer reviewed Medline, a medical supplies giant that made its market debut Wednesday.